Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
Authors:
Open Access
- 1 February 2016
- journal article
- clinical trial
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , 301-307
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and CirrhosisGastroenterology, 2014
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- The impact of hepatitis C burden: an evidence‐based approachAlimentary Pharmacology & Therapeutics, 2014
- New antiviral agents for the treatment of hepatitis C: ABT-450.Expert Opinion on Pharmacotherapy, 2014
- Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus–Coinfected Patients With Compensated CirrhosisClinical Infectious Diseases, 2013
- A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virusNature Genetics, 2013
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapyHepatology, 2009